Miami, United States:
Accumetrics, Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced the presentation of the 1-year results from the Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) registry at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting. Study findings indicate a significant association between platelet reactivity and 12-month stent thrombosis, myocardial infarction, and death. ADAPT-DES had previously demonstrated an approximately four times greater rate of stent thrombosis at 30-days in patients with high residual platelet reactivity (HRPR), as measured by Accumetrics’ VerifyNow P2Y12 Test. This association continued through follow-up, as patients with HRPR demonstrated a 2.5 times greater rate of stent thrombosis at 1-year. The VerifyNow P2Y12 Test and VerifyNow PRUTest are used to measure a patient’s platelet reactivity and the antiplatelet effect of medications such as clopidogrel and prasugrel (Plavixή and Effient).
“The 1-year results from the ADAPT-DES Registry, the largest platelet reactivity registry conducted to date, show an irrefutable association between high PRU values and thrombotic events,” said Gregg W. Stone, MD, Professor of Medicine, Columbia University, Director of Cardiovascular Research and Education, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital / Columbia University Medical Center and Principal Investigator of ADAPT-DES. “Decoupling bleeding risk from the benefit of reducing ischemic events is critically important for more potent therapies to have a positive net clinical benefit. This is an area we anticipate further exploring with ADAPT-DES data, to determine whether an optimal therapeutic window for platelet inhibition with ADP antagonists can be identified.”
Much like the commonly used PT/INR, there has been great interest within the cardiology community to identify levels of platelet reactivity where the risk for both thrombotic events and bleeding are minimized. This concept of a therapeutic window has been postulated in previously published reports.1,2,3
“The results from ADAPT-DES validate the published results from the past decade of research in the arena of platelet reactivity testing,” said Matthew J. Price, MD, Director of the Cardiac Catheterization Laboratory at Scripps Clinic, La Jolla, CA. “Thrombosis is still one of the most catastrophic events we face in the cath lab, with data demonstrating that almost 90% of stent thrombosis cases experience a recurrent MI or cardiovascular death.ΠWith the availability of generic clopidogrel and newer more potent P2Y12 inhibitors, we can use this information to aid us in providing the most cost effective and clinically appropriate treatment strategyfor our patients.”
The VerifyNow P2Y12 Test and the VerifyNow PRUTest represent the first clinically available, rapid and easy-to-use point-of-care system for measuring the level of P2Y12 receptor blockade.
“Healthcare professionals are looking for a way to balance the risks, benefits and costs of antiplatelet agents,” said Timothy I. Still, President and CEO of Accumetrics. “Guideline recommendations, the accumulation of study data from thousands of patients, and the availability of multiple treatment options are solidifying the clinical necessity of platelet reactivity testing. Accumetrics is proud to be the global leader of the platelet reactivity testing market.”
The VerifyNow System is currently used clinically by physicians in over 800 facilities in the United States and over 70 countries worldwide where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.
Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics’ VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual’s response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. clopidogrel) and GP IIb/IIIa inhibitors, the VerifyNow System provides valuable information to help physicians make informed clinical decisions. The VerifyNow P2Y12 Test and the VerifyNow PRUTest are whole blood assays used in the laboratory or point of care setting to measure the level of platelet P2Y12 receptor blockade. Additionally, the VerifyNow P2Y12 Test is indicated outside the US for evaluating the risk for recurrent events in cardiovascular patients.
For more information about the Company and its products, visit www.accumetrics.com.
The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc.
1 Campo G et al. J Am Coll Cardiol. 2011;57:2474–832 Gurbel PA et al. Am Heart J. 2010;160:346-543 Sibbing D et al. J Thromb Haemost. 2010;8:250-6
CONTACTS : Jakob Jakobsen 310-309-1003 (Office) 310-409-5351 (Cell) email@example.com or Timothy I. Still President and CEO Accumetrics 858-404-8260 firstname.lastname@example.org , ,